# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...
HC Wainwright & Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and maintains $4 pri...
Citigroup analyst Samantha Semenkow reinstates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and announces $4 price target.
HC Wainwright & Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and maintains $4 pri...